80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]林清華　吳聯(lián)平　劉加夫　陳友軒　 齊春能　林玉瓊　黃小紅　鄭　靜.晚期非小細(xì)胞肺癌患者胸水液基細(xì)胞學(xué)蠟塊中新抗體D5F3檢測的臨床價值[J].福建醫(yī)藥雜志,2019,41(01):3-5.
　LIN Qinghua,WU Lianping,LIU Jiafu,et al.Clinical value of D5F3 in hydrothorax fluid based cytological wax block in patients with advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(01):3-5.
點(diǎn)擊復(fù)制

晚期非小細(xì)胞肺癌患者胸水液基細(xì)胞學(xué)蠟塊中新抗體D5F3檢測的臨床價值()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
41
期數(shù):
2019年01期
頁碼:
3-5
欄目:
臨床研究
出版日期:
2019-01-20

文章信息/Info

Title:
Clinical value of D5F3 in hydrothorax fluid based cytological wax block in patients with advanced non-small cell lung cancer
文章編號:
1002-2600(2019)01-0003-03
作者:
林清華　吳聯(lián)平　劉加夫　陳友軒　 齊春能　林玉瓊　黃小紅　鄭　靜
福建醫(yī)科大學(xué)教學(xué)醫(yī)院福建省福州肺科醫(yī)院病理科(福州350008)
Author(s):
LIN Qinghua; WU Lianping; LIU Jiafu; CHEN Youxuan; QI Chunneng; LIN Yuqiong; HUANG Xiaohong; ZHENG Jing.
Department of Pathology, Fuzhou Pulmonary Hospital,Teaching Hospital of Fujian Medical University,Fuzhou,Fujian 350008, China
關(guān)鍵詞:
D5F3; 非小細(xì)胞肺癌; 胸水液基; 細(xì)胞學(xué)蠟塊; ALK蛋白
Keywords:
D5F3;  non small cell lung cancer;  hydrothorax liquid-based;  Cell block;  ALK protein
分類號:
R365;R734.2
文獻(xiàn)標(biāo)志碼:
A
摘要:
目的　探討晚期非小細(xì)胞肺癌患者胸水液基細(xì)胞學(xué)蠟塊中ALK 新抗體D5F3檢測的臨床價值.方法　選 擇200例經(jīng)胸膜活檢確診的非小細(xì)胞肺癌且胸水發(fā)現(xiàn)癌細(xì)胞患者的胸水,將其制成液基細(xì)胞學(xué)蠟塊,應(yīng)用ALK 新型抗體 D5F3檢測該基因蛋白表達(dá)情況,分別從陰性、陽性(1~3＋)對比其在兩種標(biāo)本中的表達(dá)異同.結(jié)果　200例液基細(xì)胞學(xué) 蠟塊標(biāo)本檢測顯示,9例ALK陽性(1~3＋),191例ALK (－),陽性率4.5％.陽性胸水的組織學(xué)類型均為腺癌,其中, 1例(＋),5例(2＋),3例(3＋);≤60歲的6例,＞60歲的3例(中位年齡51歲),差異有統(tǒng)計(jì)學(xué)意義(P ＜0.05); 男性5例,女性4例.與同一患者的胸膜活檢標(biāo)本ALK表達(dá)情況完全一致,符合率為100％.結(jié)論　ALK 蛋白陽性多見于 晚期肺腺癌中較年輕的患者,D5F3新抗體在晚期NSCLC患者的胸膜活檢組織及胸水液基細(xì)胞學(xué)蠟塊中表達(dá)情況一致.胸 水液基細(xì)胞塊可作為檢測ALK蛋白的樣本.對原發(fā)性肺腺癌合并胸膜轉(zhuǎn)移出現(xiàn)惡性胸腔積液的患者,可根據(jù)胸腔積液沉渣 包埋標(biāo)本ALK蛋白表達(dá)指導(dǎo)臨床靶向治療.
Abstract:
Objective To analyze the clinical value of ALK new antibody D5F3 in the application of hydrothorax liquid-based cytological wax blocks in patients with advanced non-small cell lung cancer. Methods The pleural effusions of 200 patients diagnosed as non-small cell lung cancer by pleural biopsy and with cancer cell found in the pleural effusion were chosen,and were made into liquid based cytology wax block. ALK D5F3 new antibody(CST company)was applied to detect the gene protein expression. The similarities and differences of the expression in the two kinds of specimens were compared respectively from the negative and positive(1-3+). Results The results showed that 9 cases were ALK positive(1-3+)and 191 cases were ALK negative(-). There were one case(+),five cases(2+)and three cases(3+). There were six patients aged less than or equal to 60 years old,three patients aged old than 60 years old and the median age was 51,with statistically significant difference(P<0.05). There were five males and four females. The expression of pleural biopsy specimen was completely consistent with that of the same patient,and the coincidence rate was 100%. Conclusion ALK protein positivity is more common in younger patients with advanced lung adenocarcinoma,and D5F3 expression is consistent in pleural biopsy tissues and hydrothorax cytological wax blocks of advanced NSCLC patients. Hydrothorax- based cells can be used as samples to detect ALK protein. For patients with malignant pleural effusion due to primary lung adenocarcinoma complicated by pleural metastasis,ALK protein expression can be detected according to pleural effusion sediment embedded specimens to guide clinical targeted treatment.

參考文獻(xiàn)/References:

[1] 徐風(fēng)華, 郭榮榮, 李欣, 等. 非小細(xì)胞肺癌患者 ERCC1 表達(dá)與鉑類藥物化療敏感性的相關(guān)性的系統(tǒng)分析[J]. 中國臨床藥理學(xué)與治療學(xué),2013, 18(1): 45-50.
[2] Zhu J, Cai L, Yang H, et al. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma[J]. Thoracic Cancer, 2014, 5(5): 411-416.
[3] 石遠(yuǎn)凱, 孫燕. 非小細(xì)胞肺癌分子靶向治療的發(fā)展趨勢[J]. 中華腫瘤雜志, 2014, 36(7): 481-484.
[4] Soda M,Choi Y L,Enomoto M,et a1.Identification of the transforming EMIA.ALK fusion geBe in non small cell lung cancer[J].Nature,2007,448(7153):561-566.
[5] Shaw A T,Yeap B Y,Mino-Kenudson M,et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EMIA-ALK[J].J Clin Oncol,2009,27(26):4247-4253.
[6] 王麗杰,郭其森.EMIA-ALK融合基因——晚期非小細(xì)胞肺癌臨床治療新靶標(biāo)[J].中華肺部疾病雜志:電子版,2014,7(1):94-97.
[7] Gridelli C,Solange P,Sgambato A,et al.ALK inhibitors in the treatment of advanced NSCLC[J].Cancer Treat Rev,2014,40(2):300-306.
[8] 朱翔,李紅威,曹寶山,等.525例肺癌中ALK陽性病例臨床病理特征研究及檢測方法探討[J].中國肺癌雜志,2014,17(3):226-232.
[9] Xia N,An J,Jiang Q Q.et al.Analysis of EGFR,EMIA-ALK,KRAS,and c-MET mutations in chinese lung adenocareinoma patients[J].Exp Lung Res,2013,39(8):328-335.
[10] 陳學(xué)敬,周立娟,董宇杰,等,Ventana全自動免疫組化法檢測不同來源肺腺癌ALK蛋白表達(dá)一致性的研究 [J]. 診斷病理學(xué)雜志, 2016, 23(4): 259-262.
[11] 陳穎,高麗麗,王彥麗,等,間變性淋巴瘤激酶陽性肺腺癌細(xì)胞病理學(xué)特點(diǎn)初探[J].中華病理學(xué)雜志,2015,44(9):628-632.
[12] Solomon B J,Mok T,Kim D W,et al.First line erizotinib versus chemotherapy in ALK.positive lung cancer[J].N Engl J Med,2014,371(23):2167-2177.
[13] 楊紅,王影,覃勝,等.漿膜腔積液細(xì)胞塊對提高細(xì)胞學(xué)診斷及開展基因檢測的價值[J].中華臨床醫(yī)師雜志:電子版,20l 3,7(21):9489-9493.
[14] 張旭超, 陸舜, 張力,等. 中國間變性淋巴瘤激酶(ALK)陽性非小細(xì)胞肺癌診斷專家共識(2013版)[J]. 中華病理學(xué)雜志, 2013, 6(42): 402-406.

相似文獻(xiàn)/References:

[1]陳新富 劉 寧 劉加夫.CK19在非小細(xì)胞肺癌淋巴結(jié)微轉(zhuǎn)移中的檢測價值(附90例分析)[J].福建醫(yī)藥雜志,2020,42(04):6.
　CHEN Xinfu,LIU Ning,LIU Jiafu..Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases[J].FUJIAN MEDICAL JOURNAL,2020,42(01):6.
[2]林 瀟 陳愉生 李鴻茹.查爾森合并癥指數(shù)及簡化合并癥評分對晚期非小細(xì)胞肺癌預(yù)后的影響[J].福建醫(yī)藥雜志,2020,42(05):23.
　LIN Xiao,CHEN Yusheng,LI Hongru.Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(01):23.
[3]李榮賓,黃延延,林賢賓,等.IGF1/RPI3K/Akt通路及其調(diào)控對非小細(xì)胞肺癌血管生成擬態(tài)形成影響的研究[J].福建醫(yī)藥雜志,2023,45(03):112.
[4]黃陽,陳靜波,林貴山.動態(tài)監(jiān)測循環(huán)腫瘤細(xì)胞對寡轉(zhuǎn)移非小細(xì)胞肺癌聯(lián)合治療預(yù)后的價值[J].福建醫(yī)藥雜志,2023,45(05):8.
　HUANG Yang,CHEN Jingbo,LIN Guishan.Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2023,45(01):8.
[5]鐘穎,鄒立,陳聲池.EGFR T790M突變豐度對阿美替尼治療晚期非小細(xì)胞肺癌療效的影響[J].福建醫(yī)藥雜志,2024,46(01):17.[doi:10.20148/j.fmj.2024.01.005]
　ZHONG Ying,ZOU Li,CHEN Shengchi.Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients[J].FUJIAN MEDICAL JOURNAL,2024,46(01):17.[doi:10.20148/j.fmj.2024.01.005]

備注/Memo

備注/Memo:
基金項(xiàng)目:福州市科技計(jì)劃社會發(fā)展項(xiàng)目(2015-S-142-4)
更新日期/Last Update: 2019-01-20